Simplifying Global Compliance
FDA Panel Recommends More Hydrocodone Combo Restrictions
Washington Drug Letter
An FDA advisory panel voted 19–10 to recommend up-scheduling hydrocodone combination products to schedule II controlled substances on Jan. 25, a move that would bring tighter restrictions on the opioid painkillers.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing